Vaucher Manoela Badinelli, Silva Camila Ubirajara, Varella Ivana Rosângela Santos, Kim Arthur Yu-Shin, Kliemann Dimas Alexandre
Department of Hepatology, Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre 90050-170, Rio Grande do Sul, Brazil.
Department of Medicine, Universidade do Vale do Taquari, Lajeado 95914-014, RS, Brazil.
World J Hepatol. 2023 Aug 27;15(8):973-984. doi: 10.4254/wjh.v15.i8.973.
Hepatitis C virus (HCV) is defined as a public health problem by the World Health Organization (WHO) and since then has defined targets through the HCV elimination. The HCV cascade of care highlights the progress towards these goals and essential interventions that need to be delivered along this continuum care.
To document the treatment cascade for patients with HCV infection at the Hospital Nossa Senhora da Conceição (HNSC), defining the percentage of antibody-positive patients who collected molecular biology tests (polymerase chain reaction), attended outpatient clinic assistance, underwent treatment, and achieved a virologic cure termed sustained virologic response (SVR).
With the retrospective cohort design, patients diagnosed with HCV infection in the period between January 1, 2015 and December 31, 2020 were included. Data from HCV notification forms, electronic medical records, Computerized Laboratory Environment Manager System, and Medicine Administration System (evaluation of special medications) were collected in 2022 and all information up to that period was considered. The data were analyzed with IBM SPSS version 25, and Poisson regression with robust simple variance was performed for analysis of variables in relation to each step of the cascade. Variables with < 0.20 were included in the multivariate analysis with < 0.05 considered significant. Pearson's chi-square test was applied to compare the groups of patients who persisted in follow-up at the HNSC and who underwent follow-up at other locations.
Results were lower than expected by the WHO with only 49% of candidates receiving HCV treatment and only 29% achieving SVR, despite the 98% response rate to direct acting antivirals documented by follow-up examination. The city of origin and the place of follow-up were the variables associated with SVR and all other endpoints. When comparing the cascade of patients who remained assisted by the HNSC external patients, we observed superior data for HNSC patients in the SVR. Patients from the countryside and metropolitan region were mostly assisted at the HNSC and the specialized and continuous care provided at the HNSC was associated with superior results, although the outcomes remain far from the goals set by the WHO.
With the elaboration of the HCV cascade of care using local data, it was possible to stratify and evaluate risk factors associated with losses between each step of the cascade, to inform new strategies to guide elimination efforts in the future.
丙型肝炎病毒(HCV)被世界卫生组织(WHO)定义为一个公共卫生问题,自那时起便通过消除丙肝病毒确定了目标。丙肝病毒的连续照护流程突出了在实现这些目标方面取得的进展以及在这一连续照护过程中需要提供的必要干预措施。
记录圣母受孕医院(HNSC)丙肝病毒感染患者的治疗流程,确定进行分子生物学检测(聚合酶链反应)、接受门诊治疗、接受治疗并实现病毒学治愈即持续病毒学应答(SVR)的抗体阳性患者的比例。
采用回顾性队列设计,纳入2015年1月1日至2020年12月31日期间被诊断为丙肝病毒感染的患者。2022年收集了丙肝病毒报告表、电子病历、计算机化实验室环境管理系统和药物管理系统(特殊药物评估)中的数据,并考虑了截至该时期的所有信息。使用IBM SPSS 25版对数据进行分析,并进行稳健简单方差的泊松回归以分析与治疗流程各步骤相关的变量。将<0.20的变量纳入多变量分析,<0.05被视为具有统计学意义。应用Pearson卡方检验比较在HNSC持续接受随访的患者组和在其他地点接受随访的患者组。
结果低于WHO的预期,尽管随访检查记录的直接作用抗病毒药物的应答率为98%,但只有49%的患者接受了丙肝病毒治疗,只有29%的患者实现了SVR。患者的原籍城市和随访地点是与SVR及所有其他终点相关的变量。在比较仍由HNSC提供照护的患者组与外部患者时,我们观察到HNSC患者在SVR方面的数据更优。来自农村和大都市地区的患者大多在HNSC接受照护,HNSC提供的专业和持续照护与更优的结果相关,尽管结果仍远未达到WHO设定的目标。
通过利用本地数据制定丙肝病毒连续照护流程,能够对治疗流程各步骤之间与失访相关的风险因素进行分层和评估,为未来指导消除丙肝努力的新策略提供依据。